In last few years, drugs targets immune checkpoint molecules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1) brought about a major paradigm shift in cancer treatment.
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
In last few years, drugs targets immune checkpoint molecules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1) brought about a major paradigm shift in cancer treatment. These immune checkpoint inhibitors (ICIs) enhanced the overall survival of a variety of malignancies such as malignant melanoma and non-small lung cancer. Apart from this, several ongoing clinical trials are also evaluating other immune checkpoint molecules such as lymphocyte activation gene -3 (LAG-3), TIM-3, TIGIT, and others. Therefore, it is believed that more and more patients will adopt novel immune checkpoint inhibitor therapy in coming years.
However, despite their improved clinical outcomes, the efficacy remains limited and tumor regression have not been obtained in many cancer patients. Apart from this, the immune checkpoint inhibitor therapy is also associated with several immune related adverse events. To mitigate these challenges, the research is mainly inclined towards development of biomarkers to predict tumor response and occurrence of adverse events. Biomarkers are novel biological molecules or genes which have their presence in blood and other body fluids. These are naturally occurring substances which are identified using bioinformatics and play a significant role in finding and understanding diseases and their behaviors. For example, blood pressure, platelets count is biomarkers as they help in the diagnosis of leukemia. Apart from this, various predictive and prognostic biomarkers have also been developed which assist doctors in the prescription of personalized medicines to patients.
Several ongoing clinical trials are evaluating the role of novel biomarkers in response to immune checkpoint therapy which have shown positive response. For instance, a recent study demonstrates that germline microRNA-based biomarkers accurately predicted grade 2 or higher immune-related adverse events associated with anti-PD-1/PD-L1 therapy among patients with various cancer types. Apart from this, in patients with non-small cell lung cancer treated with immune checkpoint inhibitors, tumor mutational burden (TMB) has found to be predictive potential.
The biotechnology sector is continuously investing in research and development activities related to biomarkers for new product launches in the market. For instance, EpiSwitch CIRT developed by Oxford BioDynamics has also gained approval from US FDA. The first-of-its-kind clinical blood test predicts the likelihood of a cancer patient’s response to immune checkpoint inhibitors including anti-PD-L1 and anti-PD-1 immunotherapies. Moreover, Personalis announced a strategic alliance with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies. The collaboration will bring Personalis’ leading comprehensive genomic tumor profiling test to UC San Diego health care professionals and their cancer patients to help guide FDA-approved therapy decisions, as well as clinical trial treatment options.
The future of the cancer immune checkpoint inhibitor biomarker market looks promising with opportunities in the diagnostics, research, prognostics, and risk assessment. As per our report findings, the global immune checkpoint inhibitor biomarker market will surpass US$ 28 Billion by 2028. One of the major factors expected to increase demand for immune checkpoint inhibitor biomarkers is the paradigm shift toward personalized medicine for cancer treatment due to absence of standard diagnosis and treatment. In addition, the market is driven by rising worldwide incidence of cancer and higher acceptance of immune checkpoint inhibitor therapies in developing countries, the paradigm change in healthcare from illness diagnosis to risk assessment or early diagnosis, and the increased use of biomarkers in drug development.
Our report Immune checkpoint inhibitor biomarker market provides in-depth analysis on market size, share, recent development, and trends. The report also provides comprehensive analysis on the clinical trials related to biomarkers in various phases and across different indications. Aside from this, report also gives description of competitive landscape to help investors, key players, and new entrants gain a significant portion of the global market.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com